No increase in anti-A isohemagglutinin titer after SARS-CoV-2 infection: A retrospective cohort analysis of group O apheresis platelet donors

J Clin Apher. 2021 Dec;36(6):882-885. doi: 10.1002/jca.21942. Epub 2021 Sep 30.

Abstract

The risk of a hemolytic reaction during the transfusion of ABO non-identical PC is determined by the presence of natural anti-A IgM antibodies, the titer of which may increase after infections. The aim of the study was to evaluate the titer of anti-A isohemagglutinins in platelet concentrate (PC) obtained by apheresis from group O donors who experienced SARS-CoV-2 infection, and to compare the titer before and after infection. A retrospective single-center analysis of 21 PC donors with a previous COVID-19 history was performed. The results showed neither a statistically important increase in the anti-A IgM antibody titers nor a significant correlation between the anti-A IgM antibody level and anti-SARS-CoV-2S1 antibody titer in the donors with an asymptomatic or mild COVID-19. Further population-based studies on anti-A titers are necessary for a comprehensive assessment of this phenomenon.

Keywords: COVID-19; SARS-CoV-2; isohemagglutinin; platelet; transfusion.

MeSH terms

  • ABO Blood-Group System / immunology
  • Adult
  • Antibodies, Viral / blood
  • Blood Donors
  • COVID-19 / blood*
  • COVID-19 / immunology*
  • Cohort Studies
  • Female
  • Hemagglutinins / blood*
  • Humans
  • Immunoglobulin M / blood
  • Male
  • Middle Aged
  • Platelet Transfusion / adverse effects
  • Plateletpheresis*
  • Retrospective Studies
  • SARS-CoV-2* / immunology
  • Transfusion Reaction / blood
  • Transfusion Reaction / etiology
  • Transfusion Reaction / immunology
  • Young Adult

Substances

  • ABO Blood-Group System
  • Antibodies, Viral
  • Hemagglutinins
  • Immunoglobulin M